Cargando…
Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors
Pharmacological treatment of Duchenne muscular dystrophy (DMD) with histone deacetylase inhibitors (HDACi) is currently being tested in clinical trials; however, pre‐clinical studies indicated that the beneficial effects of HDACi are restricted to early stages of disease. We show that FAPs from late...
Autores principales: | Consalvi, Silvia, Tucciarone, Luca, Macrì, Elisa, De Bardi, Marco, Picozza, Mario, Salvatori, Illari, Renzini, Alessandra, Valente, Sergio, Mai, Antonello, Moresi, Viviana, Puri, Pier Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171680/ https://www.ncbi.nlm.nih.gov/pubmed/35383427 http://dx.doi.org/10.15252/embr.202254721 |
Ejemplares similares
-
HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles
por: Saccone, Valentina, et al.
Publicado: (2014) -
Fibro-adipogenic progenitors of dystrophic mice are insensitive to NOTCH regulation of adipogenesis
por: Marinkovic, Milica, et al.
Publicado: (2019) -
Metabolic reprogramming of fibro/adipogenic progenitors facilitates muscle regeneration
por: Reggio, Alessio, et al.
Publicado: (2020) -
SCA-1 micro-heterogeneity in the fate decision of dystrophic fibro/adipogenic progenitors
por: Giuliani, Giulio, et al.
Publicado: (2021) -
Dynamics of cellular states of fibro-adipogenic progenitors during myogenesis and muscular dystrophy
por: Malecova, Barbora, et al.
Publicado: (2018)